| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5605371 | International Journal of Cardiology | 2016 | 10 Pages |
Abstract
This study demonstrates that AAV9-mediated JPH2 gene therapy maintained cardiac function in mice with early stage heart failure. Moreover, restoration of JPH2 levels prevented loss of T-tubules and suppressed abnormal SR Ca2Â + leak associated with contractile failure following TAC. These findings suggest that targeting JPH2 might be an attractive therapeutic approach for treating pathological cardiac remodeling during heart failure.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Julia O. Reynolds, Ann P. Quick, Qiongling Wang, David L. Beavers, Leonne E. Philippen, Jordan Showell, Giselle Barreto-Torres, Donna J. Thuerauf, Shirin Doroudgar, Christopher C. Glembotski, Xander H.T. Wehrens,